Avrobio’s ongoing FAB-GT Phase 2 clinical trial, testing its experimental gene therapy AVR-RD-01 in adolescents and adults with Fabry disease, is now open to female patients.
The protocol amendment, implemented in August, allows girls and women with Fabry to participate in the trial, even though their symptoms are usually milder than those of male patients.
Read the press release